BioVie (BIVI) Faces Securities Fraud Class Action After Uncovering Potential Scientific Misconduct In Failed Phase 3 Clinical Trial – Hagens Berman
SAN FRANCISCO, Feb. 16, 2024 (GLOBE NEWSWIRE) — Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now. Class Period: Aug. 5, 2021 – Nov. 29, 2023Lead Plaintiff Deadline: Mar. 19, 2024Visit: www.hbsslaw.com/investor-fraud/BIVI Contact An Attorney Now: BIVI@hbsslaw.com … Read more